Tonix Pharmaceuticals Holding Corp. (TNXP)

0,1840 -0,0060 (-3,16%) Alla chiusura: 04:00PM EDT

Tonix Pharmaceuticals Holding Corp.

26 Main Street
Suite 101
Chatham, NJ 07928
United States
862 799 8599
https://www.tonixpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 103

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Seth Lederman M.D.	Co-Founder, President, CEO & Chairman	675k	N/D	1958
Mr. Bradley Saenger CPA	CFO & Treasurer	640,77k	N/D	1974
Mrs. Jessica Edgar Morris	Chief Operating Officer	654,55k	N/D	N/D
Dr. Gregory M. Sullivan M.D.	Chief Medical Officer & Secretary	661,44k	N/D	1966
Dr. Herbert W. Harris M.D., Ph.D.	Executive Vice President of Translational Medicine	N/D	N/D	N/D
Ms. Siobhan Fogarty B.Sc., M.Sc.	Executive Vice President of Product Development	N/D	N/D	N/D
Dr. Darryl Rideout Ph.D.	Executive Vice President of Experimental Chemistry	N/D	N/D	N/D
Dr. Sina Bavari Ph.D.	Executive Vice President of Infectious Disease Research & Development	N/D	N/D	N/D
Dr. Zeil Rosenberg M.D., M.P.H.	Executive Vice President of Medical	N/D	N/D	N/D
Mr. James R. Hunter M.B.A.	Executive Vice President of Commercial Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Tonix Pharmaceuticals Holding Corp. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.